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The First Regional Healthy Aging and Dementia Research Symposium, organized by the Garrison Institute on Aging (GIA) of the Texas Tech University Health Sciences Center (TTUHSC), was held in Lubbock, Texas, October 24-25, 2018 . The Symposium joined experts from educational and research institutions across the United States. The purpose of the Symposium was to discuss the latest research in healthy aging and dementia, public health trends related to neurodegenerative diseases of aging, and community-based programs and research studying health, nutrition, and cognition.
The two-day Symposium included all GIA staff and researchers. Students, postdoctoral fellows, and faculty members involved in dementia research presented at the Symposium. In addition, healthcare professionals, from geriatricians to social workers working with patients with neurodegenerative diseases, also presented. This event was comprised of multiple sessions, each with several oral presentations, followed by questions and answers, and discussion.
Symposium planning began in June of 2018. Invitations were sent to experts across the United States, who had knowledge of and experience in the fi elds of healthy aging and dementia research in neurodegenerative diseases.
The GIA staff collaborated with the TTUHSC Offi ce of Marketing and Communications to publicize the Symposium to academic and research communities across the United States and to the community at large. Media outlets that we used to publicize the Symposium were TTUHSC Statline, which is an internal newsletter for TTUHSC, and the Daily Dose website. Media releases were distributed to local and regional media groups, including the Lubbock Avalanche Journal and the Lubbock Daily Toreador. A media release was submitted to EurekAlert. Facebook, and Twitter posted information about the Symposium, and the journal Aging Research News ran information on its Twitter page. Another planning component included a user-friendly website with a link to take interested persons to a registration
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On Day 2, Dr. Reddy introduced Tedd L. Mitchell, the President of TTUHSC and Chancellor of TTU System, who addressed three key aspects of aging: genetics, behavior and environment. Dr. Mitchell validated how research in the laboratory and in community-based educational programs is necessary for developing programs to promote healthy aging. We thank President Mitchell, who connected research with application to the community in his presentation. research plans. Russell Swerdlow gave a talk on his pioneering work on mitochondrial cytoplasmic hydrids or 'cybrids' and their effects on ketogenic diet on dementia. It was exciting to learn about his research in ketosis and dementia, which he is conducting at the University of Kansas. Marcia Ory from Texas A&M provided insight into communitybased projects that educate the public about the impact of lifestyles on dementia and the onset of neurodegenerative diseases. Parvalbumin In my laboratory, we focus on the mechanisms of neurodegeneration in Alzheimer's disease (AD) and related disorders such as Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). We utilize various molecular, biochemical, cell biological, advanced imaging, and animal modeling (mouse & C. elegans) tools to answer important questions pertinent to healthy vs. pathological brain aging. I have been actively engaged in neurodegeneration and Alzheimer's disease (AD) research for the past 22 years. Specifi cally, we are currently interested in 1) the mechanisms of Abeta production and neurotoxicity, 2) signal transduction mechanisms between Abeta and tau, 3) interplay between pathogenic proteins such as tau and the UPR and chaperone systems, 4) mechanisms underlying mitochondrial dysfunction in AD and FTD/ALS, 5) role of selective autophagy and mitophagy in the accumulation of toxic components, and 6) the study of extracellular vesicles (i.e., exosomes) as disease biomarkers and agents of neurodegeneration. Of interest, we have shown that the Slingshot-cofi lin activation plays a key role in both Abeta-mediated neurodegenerative changes. We are currently working on a series of Slingshot inhibitors that antagonize this pathway of Abeta-induced neurotoxicity. We have recently shown that a scaffolding protein RanBP9, which is elevated in brains of AD patients and promotes Abeta production, also positively regulates tauopathy via its direct interactions with tau and Hsp90/Hsc70 complexes. Our studies with the novel FTD/ALS gene CHCHD10 showed that CHCHD10/har-1 plays an essential role in mitochondrial function, longevity, and movement behavior in C. elegans. Wild type human CHCHD10 but not the ALS/FTD CHCHD10 mutants rescued all of Quentin Smith, PhD Quentin Smith's primary research interests are focused on assessing and ultimately improving drug delivery across the blood-brain barrier for the treatment of brain tumors, stroke, and neurodegenerative disease. He has established highly sensitive, regiospecifi c methods to map the distribution of low levels of bound and free drug in brain and brain metastases of breast cancer following systemic drug administration in animals. His lab is dissecting the roles of key BBB transporters in controlling brain and brain metastasis exposure of drugs. Also, he is working on developing and evaluating modifi ed drugs that are specifi cally designed to circumvent the BBB. Both novel carrier vectors to deliver conventional drugs and rational design of drug modifications that retain chemotherapeutic activity while circumventing the transporters that limit brain access are being investigated. Research is funded by the Cancer Prevention Research Incentive of Texas (CPRIT), DoD, NIH, and numerous collaborations with industry. . During his term, he was engaged in efforts that changed the President's test from one that was fi tness based to one that is health based. Dr. Mitchell is married to Dr. Janet Tornelli-Mitchell. They met while in medical school and practiced together for nearly two decades. The Mitchells have three children, Katherine, an assistant district attorney in Dallas, Charlie, a petroleum engineer in Houston, and Chris, an undergraduate student at Texas Tech University. Abstract: The purpose our study is to assess the impact of healthy diets and regular exercise on dementia in elderly individuals and patients with early Alzheimer's disease (AD). Our presentation identifi es various modifi able and non-modifi able risk factors, and also outlines the evidence for lifestyle changes associated with the reduced risk of dementia. Currently, over 50 million people are living with Alzheimer's and other forms of dementias worldwide. Annual estimated health care cost is about $818 billion and are projected to be $2 trillion by 2050. Currently, there are no drugs that can delay and/or prevent the progression of disease in elderly individuals and in patients with Alzheimer's. Extracellular amyloid deposits and intracellular neurofibrillary tangles are the major pathological hallmarks. Loss of synapses and synaptic damage are the best correlates of cognitive decline in Alzheimer's disease patients. Two thirds of women and one third of men are at lifetime risk for AD. Multiple sites are affected by disease, including entorhinal cortex, temporal cortex, fronto-parietal cortex, hippocampus and subcortical nuclei. Synaptic damage and mitochondrial dysfunction are early events in disease progression. Causal factors are known for about 1-2% of total AD patients. Mutations in amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) genes are involved in early onset AD. Several risk factors have been identifi ed, including Apolipoprotein E4 genotype, type 2 diabetes, traumatic brain injury, depression and hormonal imbalance and these are reported to associate with late-onset sporadic AD. Recent research revealed that antioxidants enriched diets and regular exercise development from Indiana University, doctorate in family studies and human development from Purdue University and Master of Public Health in chronic disease epidemiology and behavioral sciences from John Hopkins University Bloomberg School of Public Health.
Salvatore Oddo, PhD
Dr. Oddo received his undergraduate degree in Molecular Biology from the University of Catania, Italy, and his graduate degree in Neurobiology of Learning and Memory from the University of California, Irvine. Dr. Oddo's research focuses on understanding the molecular mechanisms underlying memory defi cits in Alzheimer's disease. Using animal models, he showed that dysfunction signaling transduction pathways that are critical for learning and memory play a pivotal role in the cognitive decline associated with Alzheimer's disease. Recently, he showed that necroptosis, a programmed form of necrosis, contributes to neuronal loss in Alzheimer's disease. Dr. Oddo has published more than 90 research articles in international peer-reviewed journals, which have been cited more than 24,000 times. In recognition of his contribution to the aging and Alzheimer's disease fi elds, he has been the recipient of several national and international awards. 
Abstract:
The purpose of our study is to understand gene expression profi les of different brain regions of postmortem Alzheimer's disease (AD) brains. RNA sequencing (RNA-Seq) expansions enabled the transcriptome analysis of lethal genes in Alzheimer's disease (AD) condition with an unbiased manner. The RNA-Seq data analysis underlying functional heterogeneity of the genes in disease and normal states may provide the better information in order to understand the disease mechanisms in AD. However, the probabilistic methods of gene expression profi les infl uence probability with robust models may allow critical analysis of the gene expression data, protein localizations and pathway interactions to dissect the disease/normal states in a systemic way. Results from our RNA-Seq data showed that among six genes from frontal (FITM1, NFKBIA, SLC25A29, RPPH1, IFI27, AHSA1), seven genes from temporal (HOMEZ, LINC01550, ESR2, EFCAB11, GPR65, OTX2-AS1, and DHRS4L2) and three genes from other regions (LOC101927045, LINC01551 and IFI27) were upregulated in Ad brains relative to reduces toxic radicals, enhances mitochondrial and synaptic functions, and improve cognitive health in elderly individuals. Presently available data on the use of antioxidants in transgenic mouse models of AD and antioxidant(s) supplements in diets of elderly individuals were critically assessed. We also assessed the use of antioxidants in randomized clinical trials in AD patients. Overall, our presentation discusses the current status of healthy diets and regular exercise on dementia in elderly individuals. Abstract: The purpose of our study is to explore the protective effects of mitochondria-targeted small molecules in Alzheimer's disease (AD). Mitochondrial dysfunction is a hallmark characteristic of AD as well as numerous neurodegenerative diseases. Quality of mitochondria is important to maintain cellular ATP and function. Damaged mitochondria yield impairment to bioenergetics and mitochondrial dynamics, which result in defective synaptic function, neuronal damage and loss of cognition. Drugs, which have included cholinesterase and glutamate inhibitors, augment neurotransmitters and help curtail loss of cognition, but fail to address mitochondrial damage. Increasing evidence suggests that daily exercise (both mental and physical) and healthy diets can improve cognitive function and alleviate AD pathology in elderly individuals and patients with AD. Several naturally occurring antioxidants, such as vitamin C & E, beta-carotene, glutathione and others tested for their effi cacies to delay the progression of dementia in AD patients. However, these natural antioxidants are unable cross the blood brain barrier and reach the sites of free radicals, mitochondria. Recently, there has been a breakthrough where researchers have been able to promote the uptake of certain antioxidants/molecules to mitochondria using positively charged lipophilic phosphonium cation. These mitochondria-targeted discovery approach provides the comprehensive and rapid drug interventions in AD and tauopathies are expected to be the prospective future therapeutic approach in AD. Abstract: Amyloid-β peptides (Aβ) are the major drivers of Alzheimer's disease (AD) and formed by successive cleavage of the amyloid precursor protein (APP) by the beta and gamma secretases. Mounting evidence suggests that Aβ and mitochondrial structural and functional abnormalities are critically involved in the loss of synapses and cognitive decline, in patients with AD. The crystal structure of the beta amyloid cleavage enzyme 1 (BACE1) protein contains the two functional domains, external and internal. The external domain is the key functional part of catalytic cleavage of c-terminal part of APP that results 38 to 42 amino acid Aβ peptide(s). In the present study, we constructed a pharmacophore BACE1 with pepstatin ligand-based screening through computational drug discovery and molecular docking. We found 3 potential ligands in our molecular docking analysis of BACE1 inhibitory ligands, and we tested all 3 BACE1 inhibitory ligands for APP processing and Aβ inhibition in AD neurons. Using biochemical, molecular, transmission electron microscopy and immunoblotting analyses, we studied ligand 1 protective effects against Aβ-induced synaptic and mitochondrial toxicities in mouse neuroblastoma (N2a) cells that express mutant APP. We found physical interaction between ligand 1 and BACE1 and this interaction decreased abnormal APP processing, reduced BACE1 activity age-matched control brains. Gene ontologies of all up regulated genes may have compensatory response disease toxicity. The upregulated genes involved in signal transduction, gene regulation and neuroinfl ammatory responses. Furthermore pathway interaction network analysis was performed with these upregulated genes. The analysis revealed highly connected functional networks with NFKBIA and Akt pathways. These genes can be recommended as some of the potential drug targets for AD. Overall, the AD Seq data provides the better understanding of differentially expressed genes and physiological relevance in normal and diseased condition. Abstract: The purpose of our study is to identify phosphorylated Tau (p-Tau) inhibitors. P-Tau has recently received great interest as a potential drug target in Alzheimer's disease (AD). The continuous failure of Aβ-targeted therapeutics recommends an alternative drug targets to treat AD. There is an increasing evidences and growing awareness of tau, plays a centric role in AD pathophysiology, including tangles formation, higher activation of phosphatases/kinases, leads p-Tau aggregation in AD neurons. In the present study, we performed computational pharmacophore-based models, molecular docking and simulation studies for p-tau in order to identify hyperphosphorylated sites. We found multiple Serine and Tyrosine sites that alter the R1/R2 repeats in tau protein. The ligand molecules exhibiting the p-O ester scaffolds with inhibitory and/or blocking actions against Serine and Tyrosine of ptau. Our molecular docking screening revealed fi ve ligands with high docking scores and optimal protein-ligand interactions of p-tau. These fi ve ligands showed the best pharmacokinetic and physicochemical properties, including good absorption, distribution, metabolism, and excretion (ADME) and admetSAR toxicity. The p-tau pharmacophore drug
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dimorphism in progression as well as the outcome of the treatment. Methods: In the current study, we investigated global gene expression analysis using healthy control human and rhesus raphe tissues of the isodendritic core. Brain tissues were obtained from Neuro-Biobank Tissue Repository and Oregon National Primate Research Center Tissue Bank. RNA was isolated from raphe region of 4 groups (5 males and 5 females human DRN, 5 males and 5 females rhesus macaques DRN). In experiment 1, rhesus raphe RNA samples were hybridized to the rhesus specifi c chip (TAQ4.1 Affymetrix). Data were analyzed using transcriptome analysis console software between male and female rhesus macaques. In experiment 2, human raphe RNA samples were hybridized to Clariom D human chip and rhesus chip. Data were analyzed between males and females and also between humans and rhesus macaques. In experiment 3, differentially expressed genes were verifi ed using Eva-Green chemistry based real-time qRT-PCR. Results: Gene expression data revealed that electron transport chain (OXPHOS) and olfacotry receptor genes were upregulated in humans relative to rhesus macaques. On the other hand, genes related to copper & zinc homeostasis, EGFR, VEGF, BDNF, MAP K, NRF2 signaling, monoamine transport and signaling were upregulated in rhesus macaques relative to humans. MicroRNAs related to muscles, lymphocytes, and epithelium were upregulated in rhesus macaques relative to humans. The genes related to focal adhesion, Alzheimer's disease, electron transport, insulin signaling, BDNF, acin cytoskeleton, VEGF, circadian rhythm, G-protein, leptin, WNT signaling are upregulated in males relative to females in both humans and rhesus. Further, genes related to olfactory receptor, immune interaction with lymphoid and non lymphoid cells, TNFR2, DNA synthesis and replication were regulated in females relative to males in both humans and rhesus macaques. Overall, our study provides gender-and species-specifi c based fi ndings in the brainstem of humans and rhesus macaques. 
Abstract:
The purpose of our study is to understand the role of brainstem in the progression and pathogenesis of Alzheimer's disease. Normal aging of the brain is governed by adaptive cellular degeneration, the rate of synaptogenesis and decreased neurogenesis. Increasing evidence suggests that the levels of neurotransmitters are reduced with aging, but differently expressed in males and females. Most of the neuronal degeneration thus far studied in the telencephalic region consists of the prefrontal cortex, hippocampus, temporal cortices. Brainstem nuclei are involved in the progression and pathogenesis of several neurodegenerative diseases, including Alzheimer's, Parkinson's, Fronto-temporal dementia. However, brainstem was poorly investigated area of neurodegenerative diseases. Brainstem harbor many neurons and the nuclei which synthesize neurotransmitters and neurotrophic factors. The importance of serotonin, dopamine, norepinephrine has not been investigated at protein, cellular and molecular level in the rhombencephalic region. Hypothesis: We hypothesize that isodendritic core of the brainstem is important to defi ne disease pathology of neurodegenerative as well as neuropsychiatric diseases may also have a gender 
The purpose of our study is to understand the role of MicroRNA-455-3p (MiR-455-3p) in APP processing, amyloid beta levels, mitochondrial biogenesis and synaptic activity in AD progression. Using molecular, cellular and biochemical assays, double/triple immunofl uorescence analysis and transmission electron microscopy, we studied the protective effects of miR-455-3p against 1) abnormal APP processing, 2) defective mitochondrial biogenesis and mitochondrial morphology, 3) synaptic pathology and 4) defective cell viability in neurons that express mutant APP and amyloid beta. We transfected mouse neuroblastoma (N2a) cells with mutant APP cDNA (with Swedish/Indiana mutations) and further cells were transfected with miR-455-3p (mimics and inhibitors). The N2a cells transfected with the miR-455-3p mimics exhibited healthy cell morphology and increased cell proliferation compared to the N2a cells that were transfected with the miR-455-3p inhibitor. In-silico analysis of microRNAs has identifi ed the APP gene as a putative target of miR-455-3p, and our luciferase assay confi rmed the binding of miR-455-3p at the 3'UTR of APP gene, and luciferase activity was found to be signifi cantly suppressed by miR-455-3p (P=0.002). MiR-455-3p expression was signifi cantly modulated by mimics (225-fold increase, P=0.0001) and inhibitors (-5.23-fold decrease) compared to controls. Full-length mutant APP was reduced in mutant APP cells that were transfected with the mimics and was upregulated by 2.6-fold in the N2a cells transfected with the inhibitors. Our cell viability assay showed a Abstract: MicroRNAs (miRNAs) are involved in growth, development, and occurrence & progression of many diseases. Circulating miRNAs have been used effectively as biomarkers and mechanistic targets for diseases such as stroke, Alzheimer's and cancer. MiRNA mediated post-transcriptional regulation is poorly understood in vascular biology and pathology. The purpose of this study is to determine circulatory miRNAs as early detectable peripheral biomarkers in patients with ischemic stroke (IS). In our recent global microRNA expression study, we found two previously unreported miRNAs in serum samples from patients with ischemic stroke (Vijayan et al 2018) . Further validation of differentially expressed miRNAs, we found miRNA PC-5P-12969 up-regulated in serum IS samples, postmortem IS brains, lymphoblastoid IS cell lines, oxygen-glucose deprived human and mouse neuroblastoma cells (Vijayan et al 2018) . In the present study, we sought to determine miRNA PC-5P-12969 expression levels, using quantitative real-time PCR assay (qRT-PCR) in 4 different brain regions, including hippocampus, striatum, cerebral cortex and cerebellum from 1) hypoxic-induced (HI) neonatal and control naive mice, 2) IS-affected and unaffected regions of a photothrombotic stroke model at day 1, 3, and 7 post-stroke group. Expression levels of miRNA PC-5P-12969 were signifi cantly upregulated (P=0.0005) in the hippocampi of HI mice relative to naïve control mice. In the photothrombotic stroke model, there was a signifi cant upregulation of the miRNA PC-5P-12969 expression level on day 1 post-stroke compared to the control brains. In the cerebellum, there was no change in the miRNA PC-5P-12969 expression level in HI and photothrombotic stroke models, indicating that PC-5P-12969 miRNA is specifi c to hippocampal and cortical tissues. Our silico analysis revealed that PC-5P-12969 is associated with the regulation of the stroke-related gene(s). To the best of our knowledge, this is the fi rst study identifi ed/validated potential novel candidate
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Community-level risk factors (lack of access to healthy foods and parks, increased air pollution, and rural residence) are highlighted as well. Lastly, physical activity programs (e.g., walking, yoga, swimming) and dietary interventions (e.g., Mediterranean diet, antioxidant-enriched diet) have been shown to improve cognitive function among elderly people and with mild cognitive impaired subjects. Discussion: Dementia is complex and not fully understood, though scholars have identifi ed an array of modifi able and non-modifi able risk and protective factors of dementia. As the prevalence of dementia is expected to rise with a growing aging population, further research into potential prevention strategies and treatments is warranted. Large-scale, longitudinal studies are needed to track cognition and associated risk factors over the life course in rural settings. Moreover, randomized controlled trials are needed to test the effi cacy of lifestyle interventions (i.e., dietary and physical activity programs) that aim to improve or maintain cognitive function among older adults. Abstract: Synaptic pathology and mitochondrial oxidative damage are early events in Alzheimer's disease (AD) progression. Loss of synapses and synaptic damage are the best correlates of cognitive defi cits found in AD patients. Recent research on amyloid beta (Aβ), tau mitochondria and synapses in AD revealed that Aβ and tau accumulates in synapses and synaptic mitochondria, leading to abnormal mitochondrial dynamics and synaptic degeneration in AD neurons. Further, recent studies using live-cell imaging and primary neurons from amyloid precursor protein (APP) transgenic mice revealed reduced mitochondrial mass, defective axonal transport of mitochondria and synaptic degeneration, indicating that Aβ is responsible for mitochondrial and synaptic defi ciencies. We recently found that abnormal physical interaction between signifi cantly higher population (91.35%) (P=0.014) of viable N2a cells transfected with miR-455-3p vector compared to miR-control vector. Immunoblotting and immunostaining analysis also confi rmed the downregulation of the mutant APP by miR-455-3p. We also found the reduced levels of mitochondrial biogenesis genes (PGC1α, NRF1, NRF2, and TFAM) and synaptic genes (synaptophysin and PSD95) in mutant APP cells; on the other hand, mutant APP cells that express miR-455-3p showed increased mRNA and protein levels of biogenesis and synaptic genes. Additionally, transmission electron microscopy analysis showed a decrease in the number of mitochondria and an increase in the average size of mitochondria in the N2a cells transfected with miR-455-3p. Given our fi ndings, that the miR-455-3p decrease abnormal APP processing and increase mitochondrial biogenesis and synaptic activity. Based on these observations, we cautiously conclude that miR-455-3p could be an effective therapeutic target for AD. and other dementias are neurodegenerative diseases characterized by loss of memory, cognitive impairment, and physical inability. The purpose of this presentation is to highlight prevalence and mortality data on dementia in the U.S., an overview of modifiable and non-modifi able risk and protective factors of dementia, and promising interventions that aim to maintain or improve cognitive health. Findings: Nearly 5.7 million individuals in the U.S. have AD. AD is the 6th leading cause of death in the U.S. Risk factors include age, genetics, family history, sex (women at higher risk than men), and race and ethnicity. Modifi able risk and protective factors include: education, healthy diet, and physical activity (protective factors), as well as smoking, diabetes, obesity, and traumatic brain injury (risk factors).
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Aβ-induced mitochondrial dysfunction and synaptic damage are largely involved in AD progression and pathogenesis. We recently found that abnormal physical interaction between Drp1 and Aβ, leading to excessive mitochondrial fragmentation, reduced mitochondrial fusion In the current study we continued to explore the reduced Drp1 biological functions in lieu of spatial learning and memory, synaptic numbers and mitochondrial number/size along with the expression of mitochondrial division/ fusion proteins, synaptic proteins, and biogenesis proteins in 12-month-old APPXDrp1+/-relative to the 12-month-old APP mice. Our fi ndings suggest that a partial reduction of Drp1 increased dendritic spines (Golgi-cox) may potentially be effective in ameliorating cognitive function (Morris-water maze). In addition, reduced Aβ production in APPXDrp1+/-mice eventually reduced mitochondrial dysfunction, and maintains mitochondrial dynamics, enhances mitochondrial biogenesis and synaptic plasticity. Based on these observations, we conclude that a partial reduction of Drp1 may serve as therapeutic target in preventing Alzheimer's disease. Abstract: Huntington's disease (HD) is a progressive, fatal neurodegenerative disease, characterized by chorea, seizures, involuntary movements, dystonia, cognitive decline, intellectual impairment and emotional disturbances. HD has an autosomal dominant pattern of inheritance and an age-dependent penetrance. HD is a rare disease, occurs in 4-10 per 100,000 persons, mainly of Caucasian origin. HD caused by polyglutamine (polyQ) repeat expansion within the exon 1 of HD gene, that encodes an expanded polyQ stretch in the huntingtin (Htt) protein.
Although both wild-type and mutant Htt proteins are expressed ubiquitously in the peripheral and central nervous systems, medium spiny neurons (MSNs) in mitochondrial fi ssion protein, dynamin-related protein 1 (Drp1) and Aβ and Drp1 and phosphorylated tau (p-Tau), leading to excessive mitochondrial fragmentation, reduced mitochondrial fusion and defective mitochondrial function in AD (Manczak et al 2011 Hum Mol Genet and Manczak and Reddy 2012 Hum Mol Genet) . Based on these observations, we hypothesized that a partial reduction of Drp1 inhibits and Drp1and Aβ and Drp1-pTau interactions and protects neurons from pTau-induced mitochondrial and synaptic toxicities, and maintains neuronal function in AD progression. To test our hypothesis, we created double mutant (Drp1+/-xTau) mice. Using molecular, biochemical, Golgi-cox staining and transmission electron microscopy studies, we investigated mRNA, protein levels of mitochondrial dynamics, biogenesis and synaptic genes, dendritic spines, mitochondrial number and morphology and Morris Water Maze based cognitive behavior in 12-month-old Drp1+/-xTau mice. We found significantly increased dendritic spines, signifi cantly reduced fragmented and structurally damaged mitochondria and reduced mRNA and protein levels of fi ssion genes and increased levels of fusion, biogenesis and synaptic genes in the brains of 12-monthold Drp1+/-xTau mice relative to age-matched Tau mice. Importantly, we also found ameliorated cognitive defi cits in 12-month-old Drp1+/-xTau mice relative to age-matched Tau mice. These observations strongly suggest that reduced Drp1 is benefi cial to AD neurons and may have a therapeutic value to AD patients.
Title: Reduced dynamin-related protein 1 mitigates mitochondrial fragmentation, elevates spatial learning and memory functions and elevates dendritic spines in APP transgenic mice. 
Abstract:
The purpose of our study is to understand the protective effects of reduced levels of mitochondrial fi ssion protein Drp1 against amyloid beta (Aβ) induced mitochondrial abnormalities and synaptic defi ciencies in Alzheimer's disease (AD) pathogenesis. Mounting evidence suggests that P. Hemachandra Reddy et al. / Healthy Aging and Dementia Research S27 the ability to carry out the simplest tasks. AD is also associated with synaptic loss and mitochondrial damage, selectively in learning and memory regions of the brain, including hippocampus and cortical regions of the brain. According to Alzheimer's Association, more than 50 million people, including 5.7 million Americans suffer from AD. Currently, there are no drugs that can delay and/or prevent the progression of disease in patients with Alzheimer's. Researchers found that up to 38 percent less serotonin in mild cognitive impaired subjects than cognitively healthy, age-matched counterparts. Serotonin is a hormone that transmits messages between nerve cells, and serotonin may play a key role in AD and other mental disorders. Citalopram is used to treat depression, anxiety, eating disorders and obsessive-compulsive disorder among other mood disorders. Citalopram selectively inhibits the neuronal reuptake of the neurotransmitter serotonin (5-HT) in presynaptic cells in the central nervous system, thereby increasing the levels of serotonin within the synaptic cleft and enhancing the actions of serotonin on its receptors. However, there are no studies that investigate the role of citalopram on mitochondrial dynamics, biogenesis, and autophagy/ mitophagy activities in AD. In the current study, we investigated the protective effects of citalopram against amyloid beta (Aβ)-induced mitochondrial, autophagy and synaptic toxicities in AD using mouse primary hippocampal (HT22) neurons. We transfected HT22 cells with human mutant APP (with Swe/Ind) mutations and treated with citalopram and assessed mitochondrial dynamics, biogenesis, and autophagy/mitophagy activities. We found decreased levels of mitochondrial fi ssion genes Drp1 and Fis1, increased levels of fusion genes Mfn1, Mfn2 and OPA1, increased levels of mitochondrial biogenesis genes PGC1α, Nrf1, Nrf2, TFAM, and increased levels of synaptic genes synaptophysin and PSD95 in mutant APP cells treated with citalopram relative to untreated mutant APP cells. Interestingly, we also found increased levels of mitophagy genes PNK1, TERT and autophagy genes ATG5, ATG7, LC3B and P62 in mutant APP cells treated with citalopram relative to untreated mutant APP cells. Importantly, we also found reduced levels of C-terminal fragment C99, and Aβ42 levels in mutant APP cells treated with citalopram relative to untreated mutant APP cells. Further, we also found mitochondrial number signifi cantly decreased and average mitochondrial length signifi cantly increased in mutant APP cells treated with citalopram relative the basal ganglia of selectively affected. The precise reasons for this selective neurodegeneration are not completely understood. Cellular changes occur in MSNs as the disease progresses, including the formation of inclusion bodies, calcium dyshomeostasis, impairment of axonal transport, and mitochondrial fusion/fi ssion imbalance. Further, there are no drugs/ agents that prevent disease progression in patients with HD. Recently, we designed and synthesized DDQ [diethyl (3,4-dihydroxyphenethylamino) (quinolin-4-yl) methylphosphonate] based on the structure of dopamine and tested it in Alzheimer's disease (AD) cell models and found reduced mitochondrial fi ssion and increased fusion and synaptic activity. Based these data, we hypothesize that DDQ will reduce mitochondrial fragmentation and increase synaptic activity in HD neurons. In the current study, we propose to investigate mitochondrial dynamics, biogenesis, autophagy/mitophagy and synaptic activity in both WT (STHDhQ7/Q7) and mutant striatal (STHDhQ111/Q111) neurons treated and untreated with DDQ. We will use biochemical, molecular, immunoblotting/immunofl uorescence, transmission electron microscopy and confocal microscopy techniques. Preliminarily, we tested fi ve concentrations of DDQ in both WT and mutant striatal neurons and found signifi cantly increased cell viability at 250 nM concentration. In the current presentation, we will discuss the effect of DDQ on mitochondrial dynamics, biogenesis, autophagy/mitophagy and synaptic activity.
Title: Protective Role of Citalopram Against Amyloid Beta-induced Mitochondrial, Autophagy and Synaptic Toxicities in Alzheimer's Disease the blood-based biomarkers as indicators of cognitive decline in the residents of rural west Texas. Alzheimer's disease (AD) is a slow progressive neurodegenerative disorder that destroys mental function. According to CDC over 5 million Americans are living with AD and this is expected to increase to 14 million by the year 2060. The neuropathological state of AD includes amyloid beta (Aβ) containing plaques and cytoskeletal protein, Tau containing neurofi brillary tangles in learning and memory regions of the brain. AD is of a serious public health concern. Since no cure exists for the disease, the current treatment includes effective medical management. Early diagnosis of the disease has been shown to be more effective and provide better treatment options. One of the ways to detect the presence of the disease is to measure the levels of early detectable biomarkers. Increasing evidence has been focused on studying the levels of Aβ and Tau in cerebrospinal fl uid (CSF). However, reliable methods to determine the biomarkers in blood is still being explored and more practical. Therefore, in the current study, we investigated serum samples obtained from the residents of rural West Texas, as a part of ongoing study -Project FRONTIER. In an attempt to optimize the ELISA test, we initially analyzed 80 serum samples from participants in project FRONTIER. These are either healthy controls or few people with history of depression and anxiety, in the age group 45-85 in both males and females. We tested for nine different AD biomarkers, including Aβ 40 and 42, phosphorylated Tau, soluble stacles to Healthcare Now Through Intervention, Education & Research) is an ongoing longitudinal epidemiological study exploring the natural course of chronic disease development and its impact on longitudinal cognitive, physical, social, and interpersonal functioning in a multi-ethnic sample of adults and elders living in rural communities of West Texas. There are eleven aims of Project FRONTIER and the GIA staff is working on projects associated with these aims. The fi rst aim is to evaluate the prevalence of cardiovascular disease and associated risk factors using self-report and objective assessments of risk factors. Project FRON-TIER also seeks to evaluate the prevalence of cognitive dysfunction and dementia syndromes in this rural cohort using medical, neuropsychological, and functional assessments. Another aim is to examine the link between cardiovascular disease and associated risk factors and cognitive functioning as well as the risk conveyed for dementia associated with these factors. There is also a need to evaluate the link between alcohol and substance use on cognition and healthcare status. The staff also examines healthcare disparities between ethnic groups residing within the county (primarily Mexican American and non-Hispanic white), and investigates gender differences in healthcare status. Dr. Reddy's lab staff also evaluates the link between infl ammation (via C-Reactive Protein) and cognition and the potential mediating role of this protein in the link between cognitive dysfunction and cardiovascular disease. The research lab staff also assesses bloodbased microRNAs as peripheral biomarkers in aging and neurological diseases, and evaluates coronary heart disease in males and females. Another aim is to evaluation how depression and/or anxiety impact dysfunction. ELN and mitochondrial dysfunction are each characteristic of many neurodegenerative and other diseases, and many of the genetic risk factors for these diseases modulate either ELN or mitochondrial function and impact both. Recent experimental evidence manipulating ELN and mitochondrial function frequently demonstrates a close relationship between the two. For instance, deleting autophagy genes causes mitochondrial fragmentation, and overexpressing autophagic genes rescues mitochondrial functionality in disease models. Similarly, inducing and rescuing mitochondrial dysfunction induces and rescues ELN dysfunction, respectively. Dynamin-related protein 1 (Drp1) is a mitochondrial fi ssion protein whose activity has been shown to be upregulated in neurodegenerative diseases. In mutant APP and mutant tau overexpression models, reducing Drp1 activity via genetic knockout or pharmacological inhibition by Mdivi-1 rescues both mitochondrial function and autophagy gene expression. However, the impact of these changes on ELN function is not well-characterized. Likewise, as noted above, exactly why autophagy induction (via overexpression of Beclin-1, ATG5, ATG7, TFEB, and others) rescues neurodegeneration is not clear. In part, this is because of crosstalk between these autophagy genes and other critical signaling pathways. In in vitro and in vivo model systems for AD, we propose to investigate the relationship between autophagy and mitochondrial function in relation to neurodegeneration. We will use transient and stable gene overexpression, RNA interference, immunoblotting, immunohistochemistry, ELISA, transmission electron and confocal microscopy, and other techniques. We will characterize in vitro cellular function changes that occur when ATG7 and other autophagy-inducing proteins are overexpressed in mutant APP and Tau HT-22 models. We will also characterize changes in autophagy that occur after Drp1 overexpression and knockdown. We will also conduct experiments in mutant APP transgenic mice that have hippocampus-specific fl oxed-in and fl oxed-out ATG7 alleles. These experiments will begin to "dissect" the cellular mechanisms responsible for observed improvements to AD models. Since AD model pathology has been improved through interventions that operate through entirely different mechanisms, the above approach may identify the extent to which different interventions correcting different cellular dysfunctions provides separate or overlapping benefi ts. This will give insight into whether and how each pathway might AD using the J20 mouse transgenic model that overexpresses a mutant form of human amyloid precursor protein (hAPP). We generated novel triple transgenic (3Tg) J20 +/-AD mouse models, which enable CRE recombinase-dependent expression of the red fl uorescent protein tdTomato in PV or SOM circuits, and we found signifi cant differential expression of tdTomato in PV/SOM cells in a region-and time-specifi c manner. Particularly, in 7-month-old 3Tg mice, SOM-CRE; tdTomato expression revealed a massive upregulation of SOM circuits, including a de novo SOM circuit targeting DG inner molecular layer (IML). The appearance of this de novo circuit coincides with published reports of memory defi cits and was absent from 2-month-old J20 +/-mice and age-matched J20 -/-sibling littermate controls. In contrast, PV-CRE; tdTomato expression was reduced in DG and CA3 principal cell layers in J20 +/-mice at both 2 and 7 months of age compared to J20
-/-littermate controls, suggesting an earlier global impairment of PV signaling. These novel fi ndings indicate differential alterations of PV and SOM circuitry in the etiology of AD, suggesting that disruption of PV and SOM circuits impairs spatial memory formation through divergent synaptic mechanisms. For future directions, we aim to further identifying PV and SOM neuron subpopulations that cause aberrant synaptic connections, determine synaptic consequences and cellular mechanisms of PV/ SOM dysfunction in 3Tg AD mouse models, and investigate the behavioral impact of PV and SOM dysfunction on hippocampal memory tasks. For instance, many neurodegenerative lysosomal storage diseases (LSDs)-for which ELN dysfunction is a core feature-also exhibit mitochondrial
